Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Modified LCH-III Regimen Versus Modified LCH-III Regimen Combined With Luvometinib in the Treatment of Multisystem Pediatric Langerhans Cell Histiocytosis: A Multicenter, Open-Label, Randomized Controlled Clinical Trial

NCT07431060 is registered in ClinicalTrials.gov with West China Second University Hospital as lead sponsor.

NCT NCT07431060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07431060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Modified LCH-III Regimen Versus Modified LCH-III Regimen Combined With Luvometinib in the Treatment of Multisystem Pediatric Langerhans Cell Histiocytosis: A Multicenter, Open-Label, Randomized Controlled Clinical Trial
Lead sponsor
West China Second University Hospital
Phase
Not applicable
Overall status
Recruiting
Start date
February 13, 2026
Completion date
December 31, 2030
Enrollment
120 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

langerhans cell histiocytosis (lch)